ARTA
MDGL icon

A.R.T. Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

A.R.T. Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-9,356
Closed -$807K – 1564
2019
Q3 		$807K Buy
+9,356
New +$878K 0.04% 642

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

A.R.T. Advisors's MDGL Position: Q4 2019 in Review

A.R.T. Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2019, closing a stake of 9,356 shares — an estimated $807K sold.

A.R.T. Advisors first reported a position in MDGL in Q3 2019 and held it in 1 quarter. The position peaked at $807K in Q3 2019. 120 funds tracked by Wall St. Rank hold MDGL as of Q4 2019.

  • A.R.T. Advisors reported no remaining Madrigal Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 9,356 Madrigal Pharmaceuticals shares in Q4 2019, an estimated $807K.
  • A.R.T. Advisors first reported a position in Madrigal Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • A.R.T. Advisors's Madrigal Pharmaceuticals position peaked at $807K in Q3 2019.
  • 120 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.